Wild-type TP53 Ewing (TC252, STA-ET-1, WE-68) and osteosarcoma (U20S, SJSA) cell lines were treated with XI-006 (0.5, 2.5 μM), with target gene expression assessed through real-time qPCR assays (Supplementary Fig. S3a). This evidence concerns the gene TP53 and osteosarcoma.